Boston Scientific Corp
BSX
View Detailed Chart
76.270USD
-1.380-1.78%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
113.05BMarket Cap
38.96P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-1.78%
5 Days
-18.45%
1 Month
-22.01%
6 Months
-25.92%
Year to Date
-20.01%
1 Year
-27.38%
View Detailed Chart
TradingKey Stock Score of Boston Scientific Corp
Currency: USD Updated: 2026-02-06Key Insights
Boston Scientific Corp's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 11 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 107.74.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Boston Scientific Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Boston Scientific Corp Highlights
StrengthsRisks
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 40.97% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 20.07B.
Undervalued
The company’s latest PE is 38.96, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.40B shares, decreasing 0.03% quarter-over-quarter.
Held by Mairs and Power
Star Investor Mairs and Power holds 26.18K shares of this stock.
Analyst Rating
Based on
36
analysts
Buy
Current Rating
107.741
Target Price
+38.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Boston Scientific Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Boston Scientific Corp Info
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Ticker SymbolBSX
CompanyBoston Scientific Corp
CEOMahoney (Michael F)
Websitehttps://www.bostonscientific.com/en-US/Home.html
Related Instruments
+2.98%
+0.07%
+1.60%
+2.48%
+0.31%
-1.14%
-0.05%
-2.35%
+2.65%
+2.59%
+2.03%
+2.01%
+2.38%
+1.74%
+0.16%
+0.78%
+1.72%
+0.59%
-2.02%Popular Symbols
278.120
+2.210 (+0.80%)
185.410
+13.530 (+7.87%)
68798.700
-1171.430 (-1.67%)
282.580
+22.390 (+8.61%)
2039.450
-12.280 (-0.60%)
411.110
+13.900 (+3.50%)
4952.980
+142.360 (+2.96%)
63.303
+0.206 (+0.33%)
1.182
+0.004 (+0.35%)
157.098
+0.057 (+0.04%)
